Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
Open Access
- 18 September 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 5812-5818
Abstract
Aim: To compare weight and glucometabolic outcomes of semaglutide and metabolic and bariatric surgery (MBS) for patients with type 2 diabetes and obesity. Materials and Methods: Patients treated with either semaglutide for a duration of ≥2 years or MBS in Sweden were identified within the Scandinavian Obesity Surgery Registry and the National Diabetes Registry and matched in a 1:1–2 ratio using a propensity score matching with a generalized linear model, including age, sex, glycated haemoglobin before treatment, duration of type 2 diabetes, use of insulin, presence of comorbidities and history of cancer, with good matching results but with a remaining imbalance for glomerular filtration rate and body mass index, which were then adjusted for in the following analyses. Main outcomes were weight loss and glycaemic control. Results: The study included 606 patients in the surgical group matched to 997 controls who started their treatment from 2018 until 2020. Both groups improved in weight and glucometabolic control. At 2 years after the intervention, mean glycated haemoglobin was 42.3 ± 11.18 after MBS compared with 50.7 ± 12.48 after semaglutide treatment ( p < 0.001) with 382 patients (63.0%) and 139 (13.9%), respectively, reaching complete remission without other treatment than the intervention ( p < 0.001). Mean total weight loss reached 26.4% ± 8.83% after MBS compared with 5.2% ± 7.87% after semaglutide ( p < 0.001). Conclusion: Semaglutide and MBS were both associated with improvements in weight and improved glycaemic control at 2 years after the start of the intervention, but MBS was associated with better weight loss and glucometabolic control.Keywords
Funding Information
- Stockholm läns landsting
- Region Örebro län (OLL‐939106)
This publication has 35 references indexed in Scilit:
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world dataObesity, 2023
- Benefits of weight loss of 10% or more in patients with overweight or obesity: A reviewObesity, 2022
- High acquisition rate and internal validity in the Scandinavian Obesity Surgery RegistrySurgery for Obesity and Related Diseases, 2021
- Benefits and Risks of Bariatric Surgery in AdultsJAMA, 2020
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and ObesityJAMA, 2019
- Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary DiseaseJAMA, 2019
- Registers of the Swedish total population and their use in medical researchEuropean Journal of Epidemiology, 2016
- Standardized outcomes reporting in metabolic and bariatric surgerySurgery for Obesity and Related Diseases, 2015
- Self-reported remission of obstructive sleep apnea following bariatric surgery: cohort studySurgery for Obesity and Related Diseases, 2015
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009